TNFAIP6 and inflammatory bowel disease: In-vitro expanded IT-pretreated MSCs have been reported to have a potent anti-inflammatory effect in the treatment of acute lung injury and inflammatory bowel disease animal models, which was mainly mediated by the expression of TSG6 [11–13].